- Market Capitalization, $K 1,016,967
- Shares Outstanding, K 48,682
- Annual Sales, $ 7,570 K
- Annual Income, $ -97,260 K
- 60-Month Beta 1.47
- Price/Sales 133.47
- Price/Cash Flow N/A
- Price/Book 5.12
|Period||Period Low||Period High||Performance|
| || |
+2.78 (+15.35%)since 08/30/22
| || |
+12.88 (+160.80%)since 06/30/22
| || |
+4.01 (+23.76%)since 09/30/21
Emergent BioSolutions (EBS) initiates an early-stage study evaluating its Lassa virus vaccine candidate, EBS-LASV, for the prevention of Lassa fever.
Axsome (AXSM) surges in the past three months owing to its Sunosi acquisition and promising progress on its pipeline candidate.
Here is how Pliant Therapeutics, Inc. (PLRX) and Alaunos (TCRT) have performed compared to their sector so far this year.
Pliant Therapeutics, Inc. (PLRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Pliant (PLRX) receives a positive DSMB review of the ongoing mid-stage study evaluating the company's lead candidate PLN-74809 for treating idiopathic pulmonary fibrosis.
The average of price targets set by Wall Street analysts indicates a potential upside of 127.3% in Pliant Therapeutics, Inc. (PLRX). While the effectiveness of this highly sought-after metric is questionable,...
Annovis Bio (ANVS) doses first patient in the phase III study evaluating buntanetap in early Parkinson's Disease. Stock surges.
Sorrento Therapeutics' (SRNE) stock rises after it announced positive results from its late-stage lung cancer study evaluating abivertinib.
bluebird bio (BLUE) has surged in the past three months owing to its pipeline development. The company's lead candidate recently received FDA approval as a potential treatment for beta-thalassemia.
Aeglea BioTherapeutics (AGLE) seeks a nod for its lead candidate, pegzilarginase, for treating ARG1-D in the European Union. Stock surges post announcement.
|Pliant Therapeutics Inc|
|S&P Pharmaceuticals SPDR|
|Pharmaceutical & Medical Bull 3X Direxion|
|US Pharmaceuticals Ishares ETF|
|Micro-Cap Ishares ETF|
|Invesco Nasdaq Biotechnology ETF|
|3rd Resistance Point||21.95|
|2nd Resistance Point||21.60|
|1st Resistance Point||21.25|
|1st Support Level||20.55|
|2nd Support Level||20.20|
|3rd Support Level||19.85|